84409-14-3Relevant academic research and scientific papers
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Beck, Hartmut,Thaler, Tobias,Meibom, Daniel,Meininghaus, Mark,J?ri?en, Hannah,Dietz, Lisa,Terjung, Carsten,Bairlein, Michaela,Von Bühler, Clemens-Jeremias,Anlauf, Sonja,Fürstner, Chantal,Stellfeld, Timo,Schneider, Dirk,Gericke, Kersten M.,Buyck, Thomas,Lovis, Kai,Münster, Uwe,Anlahr, Johanna,Kersten, Elisabeth,Levilain, Guillaume,Marossek, Virginia,Kast, Raimund
supporting information, p. 11639 - 11662 (2020/11/26)
Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chronic lung disease of unknown etiology. Despite the approved treatment options nintedanib and pirfenidone, the medical need for a safe and well-tolerated antifibrotic treatment of IPF remains
SYNTHESIS AND PROPERTIES OF 1-ARYL-3-OXO-1-CYCLOPENTANECARBOXYLIC ACIDS AND THEIR DERIVATIVES
Mndzhoyan, Sh.L.,Martirosyan, A.O.,Ovakimyan, A.R.
, p. 1648 - 1651 (2007/10/02)
A synthesis was developed for 1-phenyl- and 1-(alkoxyphenyl)-3-oxo-1-cyclopentanecarboxylic acids, and some of their derivatives were obtained.
